NovaBridge Biosciences

Tianjing Biotechnology (formerly Sanjing Biotechnology), established in 2014, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel or highly differentiated biologics for the treatment of diseases with significant unmet medical needs, particularly cancer and autoimmune disorders. Our mission is to bring transformative medicines to patients through innovation. Since its inception in 2016, Tianjing Biotechnology has rapidly become one of China's leading innovative biotechnology companies, successfully raising over $400 million in equity financing from our dedicated investor base, including leading healthcare funds. Our R&D capabilities encompass biologics discovery, translational medicine, chemistry, manufacturing and control (CMC), preclinical development, clinical development, and business development functions. Our deep understanding of China’s biologics regulatory framework, combined with direct access to extensive preclinical and clinical trial resources in China, further enhances these integrated capabilities. Tianjing Biotechnology is at a pivotal moment, poised to transition from a clinical-stage biotech company to a fully integrated, end-to-end global biopharmaceutical company in the coming years.